JP2006522105A5 - - Google Patents

Download PDF

Info

Publication number
JP2006522105A5
JP2006522105A5 JP2006507360A JP2006507360A JP2006522105A5 JP 2006522105 A5 JP2006522105 A5 JP 2006522105A5 JP 2006507360 A JP2006507360 A JP 2006507360A JP 2006507360 A JP2006507360 A JP 2006507360A JP 2006522105 A5 JP2006522105 A5 JP 2006522105A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
hydroxy acid
acid ester
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006507360A
Other languages
English (en)
Japanese (ja)
Other versions
JP5005339B2 (ja
JP2006522105A (ja
Filing date
Publication date
Priority claimed from US10/403,071 external-priority patent/US20040191207A1/en
Application filed filed Critical
Publication of JP2006522105A publication Critical patent/JP2006522105A/ja
Publication of JP2006522105A5 publication Critical patent/JP2006522105A5/ja
Application granted granted Critical
Publication of JP5005339B2 publication Critical patent/JP5005339B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006507360A 2003-03-31 2004-03-19 α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法 Expired - Fee Related JP5005339B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/403,071 2003-03-31
US10/403,071 US20040191207A1 (en) 2003-03-31 2003-03-31 Alpha-hydroxy acid ester drug delivery compositions and methods of use
PCT/US2004/008417 WO2004093851A1 (en) 2003-03-31 2004-03-19 Alpha-hydroxy acid ester drug delivery compositions and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012013808A Division JP5592905B2 (ja) 2003-03-31 2012-01-26 α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法

Publications (3)

Publication Number Publication Date
JP2006522105A JP2006522105A (ja) 2006-09-28
JP2006522105A5 true JP2006522105A5 (https=) 2007-05-10
JP5005339B2 JP5005339B2 (ja) 2012-08-22

Family

ID=32989847

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006507360A Expired - Fee Related JP5005339B2 (ja) 2003-03-31 2004-03-19 α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法
JP2012013808A Expired - Fee Related JP5592905B2 (ja) 2003-03-31 2012-01-26 α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012013808A Expired - Fee Related JP5592905B2 (ja) 2003-03-31 2012-01-26 α−ヒドロキシ酸エステル薬剤送達組成物及び使用方法

Country Status (14)

Country Link
US (1) US20040191207A1 (https=)
EP (1) EP1608346B1 (https=)
JP (2) JP5005339B2 (https=)
AT (1) ATE413865T1 (https=)
CA (1) CA2518918C (https=)
CY (1) CY1108700T1 (https=)
DE (1) DE602004017705D1 (https=)
DK (1) DK1608346T3 (https=)
ES (1) ES2317017T3 (https=)
MX (1) MXPA05010607A (https=)
PL (1) PL1608346T3 (https=)
PT (1) PT1608346E (https=)
SI (1) SI1608346T1 (https=)
WO (1) WO2004093851A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050238672A1 (en) * 2004-04-27 2005-10-27 Nimni Marcel E Antifungal drug delivery
DE102010013064A1 (de) 2010-03-26 2011-12-15 Gabriele Blume Neuartiges Trägersystem für den Transport von Wirkstoffen in die Haut
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
US11298336B2 (en) 2019-05-30 2022-04-12 Soluble Technologies, Inc. Water soluble formulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11786475B2 (en) 2020-07-22 2023-10-17 Soluble Technologies Inc. Film-based dosage form
US20250262183A1 (en) * 2024-02-19 2025-08-21 Harvey Tenenbaum Antibiotic Topical Composition for Absorption into Systemic Bloodstream

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492325A (en) * 1967-03-24 1970-01-27 Procter & Gamble Production of alpha-hydroxy acids and esters
US5002771A (en) * 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
CA2185600A1 (en) * 1996-09-16 1998-03-17 Bernard Charles Sherman Water-soluble concentrates containing cyclosporins
GB9621990D0 (en) * 1996-10-22 1996-12-18 Scotia Pharma Ltd Use
EP0999829A1 (en) * 1997-07-01 2000-05-17 Pfizer Products Inc. Solubilized sertraline compositions
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA01011343A (es) * 1999-05-07 2002-06-04 Pharmasol Gmbh Particulas de lipidos a base de mezclas de lipidos liquidos y solidos asi como procedimiento para su produccion.
AU5072000A (en) * 1999-06-02 2000-12-28 Hexal Ag Pharmaceutical composition for nasally administering water-soluble active substances
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations

Similar Documents

Publication Publication Date Title
JP2006522105A5 (https=)
CA2518918A1 (en) Alpha-hydroxy acid ester drug delivery compositions and methods of use
CN1236813C (zh) 水难溶性药物的自乳化组合物
ES2355439T3 (es) Parche bioerosionable.
RU2009112396A (ru) Способ программируемой плавучей доставки
ES2426963T3 (es) Preparación en forma de película con sustancias oleosas para la administración oral
CN102209534A (zh) 包封含脂肪酸油乳剂的多糖胶囊
JP2012525409A5 (https=)
KR20010041696A (ko) 발포성 장용(腸溶) 제제
JP2008534591A (ja) 疎水性溶媒内に親水性薬剤を有する組成物
CN101528196A (zh) 用于生物利用性差的药物的自乳化组合物
CN1261797A (zh) 自体乳化剂形式的亲脂性化合物的药物组合物
NZ600721A (en) Capsule formulation
JP2010523553A5 (https=)
HUP0100430A2 (hu) Strukturált glicerideket tartalmazó készítmény, valamint alkalmazása zsíroldékony vegyületek felszívódásának fokozására
CN1118571A (zh) 比沙可啶剂型
JP2008508317A5 (https=)
MX2007001187A (es) Forma de dosificacion retenida gastrica de gabapentina.
CN102892411B (zh) 含有合成的低聚糖的药物口服剂型
ES2663271T3 (es) Sistemas de administración para solubilizar ingredientes activos farmacéuticos insolubles en agua
JPH10330287A (ja) 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
AU2002356421A1 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
WO2003032896A2 (en) Dexibuprofen-containing soft gelatin capsules and process for preparing the same
AU2020272059B2 (en) Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN101889996B (zh) 含有坦索罗辛的直肠给药组合物